PerkinElmer, Inc. has reported that it has successfully completed two previously announced acquisitions that will extend its portfolio of advanced tools for cellular analysis position in area of High Content Screening.
In the fourth quarter of 2006, the Company announced its intent to acquire Euroscreen Products S.A., the Gosselies, Belgium-based developer of the AequoScreen™ cellular assay platform, and Hamburg, Germany-based Evotec Technologies, a provider of high-performance cellular screening systems.
The AequoScreen platform from Euroscreen Products is based on luminescence technology that is proven to generate quality data, while reducing the number of false positives in G protein-coupled receptor (GPCR) screening applications.
In addition, the acquisition of Euroscreen Products adds an extensive library of GPCR membranes and cell lines, which are ideal complements to the Company’s existing assay platforms.
Evotec Technologies’ product portfolio includes the Opera™ HCS platform, a tool for high content analysis that combines the precision of confocal microscopy with the throughput required for primary and secondary screening.
“The addition of Euroscreen Products’ advanced GPCR technology and Evotec Technologies’ highly regarded HCS systems to PerkinElmer’s current portfolio enables us to offer our biopharma customers a comprehensive solution in advanced cellular imaging, screening and analysis,” said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences.
Ongoing revenue of the combined entities was approximately US$25 million in 2006, and both acquisitions are expected to be neutral to slightly accretive to the Company’s 2007 earnings per share.